Insider Trading Alert - ROST, OPK And AMBA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, April 11, 2014, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $552.72 to $272,950,708.30.

Highlighted Stocks Traded by Insiders:

Ross Stores (ROST) - FREE Research Report

Bush Michael J who is Director at Ross Stores sold 57 shares at $70.09 on April 11, 2014. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 57-share transaction.

The shares most recently traded at $69.22, down $0.87, or 1.26% since the insider transaction. Historical insider transactions for Ross Stores go as follows:

  • 4-Week # shares sold: 93,668
  • 12-Week # shares sold: 93,668
  • 24-Week # shares sold: 93,668

The average volume for Ross Stores has been 2.0 million shares per day over the past 30 days. Ross Stores has a market cap of $14.8 billion and is part of the services sector and retail industry. Shares are down 7.85% year-to-date as of the close of trading on Friday.

Ross Stores, Inc., together with its subsidiaries, operates off-price retail apparel and home fashion stores under the Ross Dress for Less and dd's DISCOUNTS brand names in the United States. The company primarily offers apparel, accessories, footwear, and home fashions. The stock currently has a dividend yield of 1.09%. The company has a P/E ratio of 18.9. Currently there are 11 analysts that rate Ross Stores a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ROST - FREE

TheStreet Quant Ratings rates Ross Stores as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Ross Stores Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 20,400 shares at $9.28 on April 11, 2014. Following this transaction, the CEO & Chairman owned 139.9 million shares meaning that the stake was reduced by 0.01% with the 20,400-share transaction.

The shares most recently traded at $8.80, down $0.48, or 5.41% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.0 million shares per day over the past 30 days. Opko Health has a market cap of $3.8 billion and is part of the health care sector and health services industry. Shares are up 5.09% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 4 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ambarella (AMBA) - FREE Research Report

LeGall Didier who is Executive Vice President at Ambarella sold 15,000 shares at $27.16 on April 11, 2014. Following this transaction, the Executive Vice President owned 105,904 shares meaning that the stake was reduced by 12.41% with the 15,000-share transaction.

The shares most recently traded at $26.63, down $0.53, or 1.99% since the insider transaction. Historical insider transactions for Ambarella go as follows:

  • 4-Week # shares sold: 45,568
  • 12-Week # shares sold: 248,291
  • 24-Week # shares sold: 776,503

The average volume for Ambarella has been 1.3 million shares per day over the past 30 days. Ambarella has a market cap of $780.2 million and is part of the technology sector and electronics industry. Shares are down 22.13% year-to-date as of the close of trading on Friday.

Ambarella, Inc. develops semiconductor processing solutions for video that enable high-definition (HD) video capture, sharing, and display worldwide. The company has a P/E ratio of 26.9. Currently there are 2 analysts that rate Ambarella a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMBA - FREE

TheStreet Quant Ratings rates Ambarella as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock itself is trading at a premium valuation. Get the full Ambarella Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Tumble as Trump Calls Off North Korea Summit

Stocks Tumble as Trump Calls Off North Korea Summit

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern